HBT vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HBT presents a conflicting profile with a stable Piotroski F-Score of 4/9 and a Graham Number ($32.79) suggesting undervaluation, yet an Intrinsic Value ($17.08) that indicates significant overvaluation. While the company maintains a strong track record of earnings beats and a sustainable dividend, current growth metrics are concerning with negative YoY earnings growth (-6.30%). The bearish insider sentiment and low technical trend score offset the positive analyst recommendations, suggesting a period of stagnation or correction.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
HBT vs JPM: Head-to-Head Comparison
This page compares HBT Financial, Inc. (HBT) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.